Numinus Wellness Inc. (NUMIF)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Numinus Wellness Inc. (NUMIF) with AI Score 38/100 (Weak). Numinus Wellness Inc. is focused on developing and delivering psychedelic-assisted psychotherapy. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 15, 2026Numinus Wellness Inc. (NUMIF) Healthcare & Pipeline Overview
Numinus Wellness Inc. provides psychedelic-assisted psychotherapy solutions, operating through its Salvation Botanicals division for laboratory services and Numinus Health for therapeutic services. The company aims to transform the mental health landscape with a focus on psychotherapy, counseling, and substance abuse treatment.
Investment Thesis
Numinus Wellness Inc. presents a speculative investment opportunity in the emerging field of psychedelic-assisted psychotherapy. Key value drivers include the expansion of its Numinus Health division and the potential for increased revenue from its Salvation Botanicals laboratory services. The company's focus on mental health and substance abuse treatment aligns with growing societal needs. However, the company's negative profit margin of -207.9% and reliance on a nascent market segment pose significant risks. The high beta of 2.56 indicates substantial volatility. Successful navigation of regulatory hurdles and demonstration of clinical efficacy are crucial for long-term growth. Investors should carefully consider the risks associated with investing in an early-stage company in a highly regulated and evolving industry.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $0.01 billion indicates a micro-cap company with high growth potential but also significant risk.
- Negative P/E ratio of -1.33 reflects current unprofitability, suggesting the company is investing heavily in growth and development.
- Gross margin of 43.7% demonstrates the potential for profitability as the company scales its operations.
- Profit margin of -207.9% highlights substantial losses, requiring careful monitoring of cash flow and operational efficiency.
- Beta of 2.56 indicates high volatility compared to the market, reflecting the speculative nature of the psychedelic-assisted therapy industry.
Competitors & Peers
Strengths
- Specialized expertise in psychedelic-assisted psychotherapy.
- Integrated approach combining laboratory and therapeutic services.
- Established network of Numinus Health clinics.
- Focus on research and development in the psychedelic space.
Weaknesses
- Negative profit margin and reliance on external funding.
- Limited operating history and small market capitalization.
- High beta indicating significant volatility.
- Dependence on regulatory approvals and evolving public perception.
Catalysts
- Ongoing: Expansion of Numinus Health clinic network to increase patient access.
- Ongoing: Development of strategic partnerships to expand research and development capabilities.
- Upcoming: Potential regulatory approvals for psychedelic-assisted therapies.
- Ongoing: Increased awareness and acceptance of psychedelic-assisted therapies.
- Ongoing: Expansion of Salvation Botanicals laboratory services to new clients.
Risks
- Potential: Regulatory hurdles and evolving legal landscape for psychedelic-assisted therapies.
- Potential: Competition from other companies in the psychedelic and mental health industries.
- Potential: Negative public perception and stigma associated with psychedelics.
- Ongoing: Dependence on external funding and potential for dilution.
- Ongoing: Limited operating history and small market capitalization.
Growth Opportunities
- Expansion of Numinus Health Clinics: Numinus can expand its network of Numinus Health clinics to offer psychedelic-assisted therapy and other mental health services. The market for mental health services is substantial, with a projected value of $537.96 billion in 2030. This expansion can drive revenue growth and establish Numinus as a leading provider in the space. Timeline: Ongoing.
- Increased Utilization of Salvation Botanicals: Numinus can increase the utilization of its Salvation Botanicals division by offering comprehensive testing and research services to other companies in the psychedelic and cannabis industries. The analytical testing services market is expected to reach $13.1 billion by 2029. This can generate additional revenue streams and strengthen Numinus's position in the market. Timeline: Ongoing.
- Strategic Partnerships and Collaborations: Numinus can pursue strategic partnerships and collaborations with research institutions, pharmaceutical companies, and other healthcare providers to advance the development and delivery of psychedelic-assisted therapies. Collaborations can accelerate research, expand market reach, and enhance Numinus's credibility. Timeline: Ongoing.
- Development of Proprietary Psychedelic Formulations: Numinus can invest in the development of proprietary psychedelic formulations and delivery methods to differentiate itself from competitors and capture a larger share of the market. The market for psychedelic drugs is expected to grow significantly in the coming years. Developing innovative formulations can provide a competitive advantage and drive revenue growth. Timeline: Ongoing.
- Expansion into International Markets: Numinus can expand its operations into international markets where psychedelic-assisted therapy is legal or becoming legal. The global market for mental health services is vast, and international expansion can provide significant growth opportunities. This expansion requires careful navigation of regulatory frameworks and cultural differences. Timeline: Ongoing.
Opportunities
- Expansion of Numinus Health clinics and services.
- Increased utilization of Salvation Botanicals laboratory services.
- Strategic partnerships and collaborations with research institutions.
- Development of proprietary psychedelic formulations and delivery methods.
Threats
- Regulatory uncertainties and evolving legal landscape.
- Competition from other companies in the psychedelic and mental health industries.
- Potential for adverse clinical trial results.
- Negative public perception and stigma associated with psychedelics.
Competitive Advantages
- Specialized expertise in psychedelic-assisted psychotherapy.
- Integrated approach combining laboratory services and therapeutic services.
- Established network of Numinus Health clinics.
- Focus on research and development in the psychedelic space.
About NUMIF
Numinus Wellness Inc., headquartered in Vancouver, Canada, is dedicated to transforming the mental health landscape through the development and delivery of psychedelic-assisted psychotherapy. The company operates through two primary divisions: Salvation Botanicals and Numinus Health. Salvation Botanicals provides laboratory services, including cultivation, analytical testing, product research and development, and ancillary services related to psychedelics. It also offers comprehensive testing services for cannabis. Numinus Health focuses on providing supportive therapies and technologies aimed at healing, connection, and personal growth, with a particular emphasis on treating mental health and substance abuse. This division offers a range of services, including psychotherapy, counseling, neurofeedback, physiotherapy, and other therapies. Furthermore, Numinus Health provides training, facilities, and operational resources to practitioners in the field. The company's holistic approach aims to integrate psychedelic-assisted therapy with traditional mental health treatments, addressing a growing need for innovative solutions in mental healthcare. Numinus Wellness Inc. is committed to advancing research and development in the psychedelic space, seeking to establish itself as a leader in this emerging field.
What They Do
- Provides psychedelic-assisted psychotherapy solutions.
- Operates Salvation Botanicals division offering laboratory services.
- Offers cultivation, analytical testing, and product research for psychedelics.
- Provides full suite testing and custom testing of cannabis.
- Operates Numinus Health division providing supportive therapies.
- Offers services for psychotherapy, counseling, and neurofeedback.
- Provides training, facilities, and operational resources to practitioners.
Business Model
- Generates revenue through laboratory services provided by Salvation Botanicals.
- Generates revenue through therapeutic services offered by Numinus Health.
- Provides training and resources to practitioners in the mental health field.
Industry Context
Numinus Wellness Inc. operates within the burgeoning psychedelic-assisted therapy industry, which is gaining traction as an alternative approach to mental health treatment. The market is characterized by increasing research, evolving regulatory landscapes, and growing acceptance of psychedelics for therapeutic purposes. Competitors include companies like Algernon Pharmaceuticals Inc. (ALRTF) and PharmaTher Holdings Ltd. (ANPCY), which are also exploring psychedelic-based treatments. The industry is poised for growth, driven by the rising prevalence of mental health disorders and the limitations of conventional treatments. However, regulatory uncertainties and public perception remain significant challenges.
Key Customers
- Individuals seeking mental health and substance abuse treatment.
- Practitioners in the mental health field seeking training and resources.
- Companies in the psychedelic and cannabis industries requiring laboratory services.
Financials
Chart & Info
Numinus Wellness Inc. (NUMIF) stock price: Price data unavailable
Latest News
-
Numinus Wellness Provides Update Regarding Listing Status
newsfilecorp.com · Mar 24, 2026
-
Numinus Wellness Provides Corporate Update
newsfilecorp.com · Mar 13, 2026
-
Numinus Wellness Advises of a Change of Auditor
newsfilecorp.com · Mar 3, 2026
-
Numinus Wellness Inc. (OTCMKTS:NUMIF) Short Interest Update
defenseworld.net · Feb 2, 2026
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for NUMIF.
Price Targets
Wall Street price target analysis for NUMIF.
MoonshotScore
What does this score mean?
The MoonshotScore rates NUMIF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest News
Numinus Wellness Provides Update Regarding Listing Status
Numinus Wellness Provides Corporate Update
Numinus Wellness Advises of a Change of Auditor
Numinus Wellness Inc. (OTCMKTS:NUMIF) Short Interest Update
Leadership: Michael Tan
CEO
Michael Tan is the CEO of Numinus Wellness Inc., overseeing the company's strategy and operations in the psychedelic-assisted psychotherapy sector. His background includes experience in managing teams and driving growth in emerging markets. He is responsible for leading the company's efforts in developing and delivering innovative mental health solutions. Tan's leadership is focused on advancing research, expanding the company's network of clinics, and building strategic partnerships to accelerate growth.
Track Record: Under Michael Tan's leadership, Numinus Wellness Inc. has focused on expanding its Numinus Health division and increasing the utilization of its Salvation Botanicals laboratory services. He has overseen the development of strategic partnerships and collaborations to advance the company's research and development efforts. Key milestones include expanding the network of clinics and navigating the evolving regulatory landscape for psychedelic-assisted therapy.
NUMIF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Numinus Wellness Inc. may not meet the minimum financial standards required for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure and may not be subject to the same regulatory oversight as companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries higher risks due to the potential for limited information and liquidity.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure and regulatory oversight.
- Potential for low trading volume and illiquidity.
- Higher price volatility compared to stocks listed on major exchanges.
- Increased risk of fraud or manipulation.
- Dependence on external funding and potential for dilution.
- Verify the company's financial statements and SEC filings (if available).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's legal and regulatory compliance.
- Monitor the company's news and press releases for any red flags.
- Consult with a financial advisor before investing.
- Understand the risks associated with investing in OTC stocks.
- Operation of physical clinic locations under the Numinus Health brand.
- Provision of laboratory services through Salvation Botanicals.
- Focus on research and development in the psychedelic space.
- Presence of a management team with experience in the healthcare industry.
- Publicly available information and press releases.
What Investors Ask About Numinus Wellness Inc. (NUMIF)
What does Numinus Wellness Inc. do?
Numinus Wellness Inc. operates in the healthcare sector, focusing on psychedelic-assisted psychotherapy. The company has two divisions: Salvation Botanicals, which provides laboratory services like cultivation and testing for psychedelics and cannabis, and Numinus Health, which offers therapies for mental health and substance abuse. Numinus aims to transform mental healthcare by integrating psychedelic-assisted therapy with traditional treatments, addressing a growing need for innovative solutions in the mental health space.
What do analysts say about NUMIF stock?
As of 2026-03-15, formal analyst ratings for NUMIF are not available due to its OTC listing and small market capitalization. However, key valuation metrics include a negative P/E ratio, reflecting current unprofitability, and a high beta, indicating significant volatility. Growth considerations center on the expansion of its clinic network and the potential for regulatory approvals in the psychedelic-assisted therapy space. Investors should conduct thorough due diligence and consider the speculative nature of this investment.
What are the main risks for NUMIF?
The main risks for Numinus Wellness Inc. include regulatory uncertainties surrounding psychedelic-assisted therapies, competition from other companies in the mental health and psychedelic industries, and potential negative public perception. Additionally, the company's reliance on external funding and limited operating history pose financial risks. The OTC listing also introduces risks related to liquidity and disclosure requirements. Investors should carefully assess these risks before investing in NUMIF.
What are the key factors to evaluate for NUMIF?
Numinus Wellness Inc. (NUMIF) currently holds an AI score of 38/100, indicating low score. Key strength: Specialized expertise in psychedelic-assisted psychotherapy.. Primary risk to monitor: Potential: Regulatory hurdles and evolving legal landscape for psychedelic-assisted therapies.. This is not financial advice.
How frequently does NUMIF data refresh on this page?
NUMIF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven NUMIF's recent stock price performance?
Recent price movement in Numinus Wellness Inc. (NUMIF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Specialized expertise in psychedelic-assisted psychotherapy.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider NUMIF overvalued or undervalued right now?
Determining whether Numinus Wellness Inc. (NUMIF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying NUMIF?
Before investing in Numinus Wellness Inc. (NUMIF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- OTC market data may be limited and less reliable than data from major exchanges.